Compare Kyndryl Holdings Inc (KD) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Kymera Therapeutics Inc. Common Stock — how do they compare? Kyndryl Holdings Inc trades at $11.78 (market cap $2.67B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 3.3× Kyndryl Holdings Inc's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| KD | KYMR | |
|---|---|---|
Market Cap | $2.67B | $8.87B |
Volume | 3,966,787 | 779,107 |
Sector | Technology | Health |
52-Week High | $28.92 | $127.31 |
52-Week Low | $10.59 | $55.80 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $5.49B | $8.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $12.24, up 3.9% today, with a neutral technical signal and bearish moving averages. The company reported a return to profitability in 2025 with $252M net income after years of losses, though revenue has declined from $18.3B in 2022 to $15.1B. Recent news highlights a strategic focus on AI, including a new innovation lab and acquisitions. The stock faces mixed analyst sentiment with a consensus price target of $14.67, suggesting modest upside potential from current levels.
The outlook for KD hinges on successful execution of its AI and modernization initiatives to drive revenue growth and sustain profitability. Key risks include competitive pressures in IT services and execution challenges in integrating acquisitions. While the valuation appears reasonable with a P/S of 0.19, investors should weigh the company's turnaround progress against ongoing revenue declines and a predominantly neutral analyst rating.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
